Long Acting Beta Agonist Market, Global Outlook and Forecast 2022-2028

April 2022 | 62 pages | ID: L18D993E79ADEN
Market Monitor Global

Abstracts

Long-acting beta-agonists or long-acting beta adrenergic receptor agonists are class of drugs used in the management of asthma by relaxing the muscles surrounding the bronchial tubes and facilitating the opening the airways wider. Long-acting beta-agonists have a longer duration of action of at least 12 hours.

This report contains market size and forecasts of Long Acting Beta Agonist in Global, including the following market information:

Global Long Acting Beta Agonist Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Long Acting Beta Agonist market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Liquid Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Long Acting Beta Agonist include Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, Teva and Merck, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Long Acting Beta Agonist companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Long Acting Beta Agonist Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Long Acting Beta Agonist Market Segment Percentages, by Type, 2021 (%)

• Liquid
• Tablet

Global Long Acting Beta Agonist Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Long Acting Beta Agonist Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Ambulatory Surgical Center
• Others

Global Long Acting Beta Agonist Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Long Acting Beta Agonist Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Long Acting Beta Agonist revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Long Acting Beta Agonist revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sumitomo Dainippon Pharma
• AstraZeneca
• GlaxoSmithKline
• Boehringer Ingelheim International
• Mylan
• Teva
• Merck

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Long Acting Beta Agonist Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Long Acting Beta Agonist Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL LONG ACTING BETA AGONIST OVERALL MARKET SIZE

2.1 Global Long Acting Beta Agonist Market Size: 2021 VS 2028
2.2 Global Long Acting Beta Agonist Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Long Acting Beta Agonist Players in Global Market
3.2 Top Global Long Acting Beta Agonist Companies Ranked by Revenue
3.3 Global Long Acting Beta Agonist Revenue by Companies
3.4 Top 3 and Top 5 Long Acting Beta Agonist Companies in Global Market, by Revenue in 2021
3.5 Global Companies Long Acting Beta Agonist Product Type
3.6 Tier 1, Tier 2 and Tier 3 Long Acting Beta Agonist Players in Global Market
  3.6.1 List of Global Tier 1 Long Acting Beta Agonist Companies
  3.6.2 List of Global Tier 2 and Tier 3 Long Acting Beta Agonist Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Long Acting Beta Agonist Market Size Markets, 2021 & 2028
  4.1.2 Liquid
  4.1.3 Tablet
4.2 By Type - Global Long Acting Beta Agonist Revenue & Forecasts
  4.2.1 By Type - Global Long Acting Beta Agonist Revenue, 2017-2022
  4.2.2 By Type - Global Long Acting Beta Agonist Revenue, 2023-2028
  4.2.3 By Type - Global Long Acting Beta Agonist Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Long Acting Beta Agonist Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Ambulatory Surgical Center
  5.1.5 Others
5.2 By Application - Global Long Acting Beta Agonist Revenue & Forecasts
  5.2.1 By Application - Global Long Acting Beta Agonist Revenue, 2017-2022
  5.2.2 By Application - Global Long Acting Beta Agonist Revenue, 2023-2028
  5.2.3 By Application - Global Long Acting Beta Agonist Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Long Acting Beta Agonist Market Size, 2021 & 2028
6.2 By Region - Global Long Acting Beta Agonist Revenue & Forecasts
  6.2.1 By Region - Global Long Acting Beta Agonist Revenue, 2017-2022
  6.2.2 By Region - Global Long Acting Beta Agonist Revenue, 2023-2028
  6.2.3 By Region - Global Long Acting Beta Agonist Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Long Acting Beta Agonist Revenue, 2017-2028
  6.3.2 US Long Acting Beta Agonist Market Size, 2017-2028
  6.3.3 Canada Long Acting Beta Agonist Market Size, 2017-2028
  6.3.4 Mexico Long Acting Beta Agonist Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Long Acting Beta Agonist Revenue, 2017-2028
  6.4.2 Germany Long Acting Beta Agonist Market Size, 2017-2028
  6.4.3 France Long Acting Beta Agonist Market Size, 2017-2028
  6.4.4 U.K. Long Acting Beta Agonist Market Size, 2017-2028
  6.4.5 Italy Long Acting Beta Agonist Market Size, 2017-2028
  6.4.6 Russia Long Acting Beta Agonist Market Size, 2017-2028
  6.4.7 Nordic Countries Long Acting Beta Agonist Market Size, 2017-2028
  6.4.8 Benelux Long Acting Beta Agonist Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Long Acting Beta Agonist Revenue, 2017-2028
  6.5.2 China Long Acting Beta Agonist Market Size, 2017-2028
  6.5.3 Japan Long Acting Beta Agonist Market Size, 2017-2028
  6.5.4 South Korea Long Acting Beta Agonist Market Size, 2017-2028
  6.5.5 Southeast Asia Long Acting Beta Agonist Market Size, 2017-2028
  6.5.6 India Long Acting Beta Agonist Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Long Acting Beta Agonist Revenue, 2017-2028
  6.6.2 Brazil Long Acting Beta Agonist Market Size, 2017-2028
  6.6.3 Argentina Long Acting Beta Agonist Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Long Acting Beta Agonist Revenue, 2017-2028
  6.7.2 Turkey Long Acting Beta Agonist Market Size, 2017-2028
  6.7.3 Israel Long Acting Beta Agonist Market Size, 2017-2028
  6.7.4 Saudi Arabia Long Acting Beta Agonist Market Size, 2017-2028
  6.7.5 UAE Long Acting Beta Agonist Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Sumitomo Dainippon Pharma
  7.1.1 Sumitomo Dainippon Pharma Corporate Summary
  7.1.2 Sumitomo Dainippon Pharma Business Overview
  7.1.3 Sumitomo Dainippon Pharma Long Acting Beta Agonist Major Product Offerings
  7.1.4 Sumitomo Dainippon Pharma Long Acting Beta Agonist Revenue in Global Market (2017-2022)
  7.1.5 Sumitomo Dainippon Pharma Key News
7.2 AstraZeneca
  7.2.1 AstraZeneca Corporate Summary
  7.2.2 AstraZeneca Business Overview
  7.2.3 AstraZeneca Long Acting Beta Agonist Major Product Offerings
  7.2.4 AstraZeneca Long Acting Beta Agonist Revenue in Global Market (2017-2022)
  7.2.5 AstraZeneca Key News
7.3 GlaxoSmithKline
  7.3.1 GlaxoSmithKline Corporate Summary
  7.3.2 GlaxoSmithKline Business Overview
  7.3.3 GlaxoSmithKline Long Acting Beta Agonist Major Product Offerings
  7.3.4 GlaxoSmithKline Long Acting Beta Agonist Revenue in Global Market (2017-2022)
  7.3.5 GlaxoSmithKline Key News
7.4 Boehringer Ingelheim International
  7.4.1 Boehringer Ingelheim International Corporate Summary
  7.4.2 Boehringer Ingelheim International Business Overview
  7.4.3 Boehringer Ingelheim International Long Acting Beta Agonist Major Product Offerings
  7.4.4 Boehringer Ingelheim International Long Acting Beta Agonist Revenue in Global Market (2017-2022)
  7.4.5 Boehringer Ingelheim International Key News
7.5 Mylan
  7.5.1 Mylan Corporate Summary
  7.5.2 Mylan Business Overview
  7.5.3 Mylan Long Acting Beta Agonist Major Product Offerings
  7.5.4 Mylan Long Acting Beta Agonist Revenue in Global Market (2017-2022)
  7.5.5 Mylan Key News
7.6 Teva
  7.6.1 Teva Corporate Summary
  7.6.2 Teva Business Overview
  7.6.3 Teva Long Acting Beta Agonist Major Product Offerings
  7.6.4 Teva Long Acting Beta Agonist Revenue in Global Market (2017-2022)
  7.6.5 Teva Key News
7.7 Merck
  7.7.1 Merck Corporate Summary
  7.7.2 Merck Business Overview
  7.7.3 Merck Long Acting Beta Agonist Major Product Offerings
  7.7.4 Merck Long Acting Beta Agonist Revenue in Global Market (2017-2022)
  7.7.5 Merck Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Long Acting Beta Agonist Market Opportunities & Trends in Global Market
Table 2. Long Acting Beta Agonist Market Drivers in Global Market
Table 3. Long Acting Beta Agonist Market Restraints in Global Market
Table 4. Key Players of Long Acting Beta Agonist in Global Market
Table 5. Top Long Acting Beta Agonist Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Long Acting Beta Agonist Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Long Acting Beta Agonist Revenue Share by Companies, 2017-2022
Table 8. Global Companies Long Acting Beta Agonist Product Type
Table 9. List of Global Tier 1 Long Acting Beta Agonist Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Long Acting Beta Agonist Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Long Acting Beta Agonist Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Long Acting Beta Agonist Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Long Acting Beta Agonist Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Long Acting Beta Agonist Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Long Acting Beta Agonist Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Long Acting Beta Agonist Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Long Acting Beta Agonist Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Long Acting Beta Agonist Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Long Acting Beta Agonist Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Long Acting Beta Agonist Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Long Acting Beta Agonist Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Long Acting Beta Agonist Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Long Acting Beta Agonist Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Long Acting Beta Agonist Revenue, (US$, Mn), 2023-2028
Table 30. Sumitomo Dainippon Pharma Corporate Summary
Table 31. Sumitomo Dainippon Pharma Long Acting Beta Agonist Product Offerings
Table 32. Sumitomo Dainippon Pharma Long Acting Beta Agonist Revenue (US$, Mn), (2017-2022)
Table 33. AstraZeneca Corporate Summary
Table 34. AstraZeneca Long Acting Beta Agonist Product Offerings
Table 35. AstraZeneca Long Acting Beta Agonist Revenue (US$, Mn), (2017-2022)
Table 36. GlaxoSmithKline Corporate Summary
Table 37. GlaxoSmithKline Long Acting Beta Agonist Product Offerings
Table 38. GlaxoSmithKline Long Acting Beta Agonist Revenue (US$, Mn), (2017-2022)
Table 39. Boehringer Ingelheim International Corporate Summary
Table 40. Boehringer Ingelheim International Long Acting Beta Agonist Product Offerings
Table 41. Boehringer Ingelheim International Long Acting Beta Agonist Revenue (US$, Mn), (2017-2022)
Table 42. Mylan Corporate Summary
Table 43. Mylan Long Acting Beta Agonist Product Offerings
Table 44. Mylan Long Acting Beta Agonist Revenue (US$, Mn), (2017-2022)
Table 45. Teva Corporate Summary
Table 46. Teva Long Acting Beta Agonist Product Offerings
Table 47. Teva Long Acting Beta Agonist Revenue (US$, Mn), (2017-2022)
Table 48. Merck Corporate Summary
Table 49. Merck Long Acting Beta Agonist Product Offerings
Table 50. Merck Long Acting Beta Agonist Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Long Acting Beta Agonist Segment by Type in 2021
Figure 2. Long Acting Beta Agonist Segment by Application in 2021
Figure 3. Global Long Acting Beta Agonist Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Long Acting Beta Agonist Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Long Acting Beta Agonist Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Long Acting Beta Agonist Revenue in 2021
Figure 8. By Type - Global Long Acting Beta Agonist Revenue Market Share, 2017-2028
Figure 9. By Application - Global Long Acting Beta Agonist Revenue Market Share, 2017-2028
Figure 10. By Region - Global Long Acting Beta Agonist Revenue Market Share, 2017-2028
Figure 11. By Country - North America Long Acting Beta Agonist Revenue Market Share, 2017-2028
Figure 12. US Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Long Acting Beta Agonist Revenue Market Share, 2017-2028
Figure 16. Germany Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 17. France Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Long Acting Beta Agonist Revenue Market Share, 2017-2028
Figure 24. China Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 28. India Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Long Acting Beta Agonist Revenue Market Share, 2017-2028
Figure 30. Brazil Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Long Acting Beta Agonist Revenue Market Share, 2017-2028
Figure 33. Turkey Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Long Acting Beta Agonist Revenue, (US$, Mn), 2017-2028
Figure 37. Sumitomo Dainippon Pharma Long Acting Beta Agonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. AstraZeneca Long Acting Beta Agonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. GlaxoSmithKline Long Acting Beta Agonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Boehringer Ingelheim International Long Acting Beta Agonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Mylan Long Acting Beta Agonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Teva Long Acting Beta Agonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Merck Long Acting Beta Agonist Revenue Year Over Year Growth (US$, Mn) & (2017-2022)